Skip to content
Sign in
SWC 2026 FinalistGrand Final: Lunch Block

MedEtechni

Physician-led Puerto Rican medtech pairing 222 nm UVC wound therapy with AI clinical software; evidence still thin.

San Juan, Puerto Rico (USA), North AmericaMedTech & devices, UV phototherapy for chronic wounds + AI clinical software
Stage
Pre-seedAI integrated
Product
PilotPilots / LOIs
Funding raised
$30Kdisclosed
Founded
20188 years ago
Founders
3Kevin, Anabell…
Global score
3.5Grade DRank 111 of 151

Overview

Puerto Rican medtech developing Virgilio Rays, a non-invasive UVC phototherapy device for chronic wounds and diabetic ulcers, as well as AI-assisted clinical software.

Traction

Pilots / LOIs

Uncontrolled case study on 5 patients (chronic wounds) and multicenter before/after study on surfaces published on the website; claimed compliance (ISO 13485, IEC 60601, CE, FDA) with no clearance number; pilots offered to facilities.

Market

Chronic wound care

Chronic wounds, especially diabetic foot ulcers, are costly for health systems and drive amputations; payers and hospitals buy therapies that shorten healing time and reduce infections. Far-UVC (222 nm) is attractive because it is germicidal with lower skin risk than conventional UVC, but devices need regulatory clearance and controlled clinical evidence before hospitals adopt. Buyers are wound-care clinics, hospitals and home-health providers, reimbursed by payers.

Addressable market

2025
$13.2B
2030
$16.3B
+4.4% a year

Chronic wound care: global market from $13.2bn in 2025 to $16.3bn in 2030 (CAGR 4.4%) according to Knowledge Sourcing Intelligence.

Customers

Wound-care clinics, hospitals, diabetic foot services, home-health providers

Who signs the cheque

Hospital procurement and wound-care medical leads; payers for reimbursement

Geographies

  • Puerto Rico / United States
  • Latin America (Chile ties)

Drivers

  • Rising diabetes prevalence
  • Antimicrobial resistance pushing non-drug disinfection
  • Pressure to shorten healing times

Headwinds

  • Weak evidence (5-patient case study)
  • Unverified compliance claims
  • Reimbursement and regulatory hurdles

Global chronic wound care market from $13.2bn in 2025 to $16.3bn in 2030 (CAGR 4.4%) according to Knowledge Sourcing Intelligence.

Scalability 4/10. UV device subject to FDA/CE clearance and to clinical evidence in each market.

Market source: knowledge-sourcing.com

Technology

Category

Medical device + clinical AI software

AI integratedMachine learning / predictive

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

pilot

How it works

Virgilio Rays uses 222 nm UVC light for non-invasive wound healing and disinfection. AI tools are offered for diagnosis, triage and hospital management alongside the device.

Moat

Uncertain: far-UVC is a known technology; moat would require clinical data and clearances, which are not yet documented.

Differentiation

Non-invasive light therapy positioned for chronic wounds vs dressings and drug-based approaches.

Integration points

  • Wound imaging/measurement software
  • Hospital EHRs
  • Clinical data networks

Depends on

  • FDA/CE clearances (claimed without clearance number)
  • Controlled clinical trials
  • Device manufacturing

Use of AI

AI-assisted clinical software (diagnosis, triage, hospital management) complementing the UVC device.

Product in detail

222 nm UVC technology (Virgilio Rays) for wound healing and AI tools for diagnosis, triage and hospital management.

Business

Model
Device sales or leasing to facilities plus software (not specified).
Revenue logic
Per device or per treatment; software per facility.
Go-to-market
Pilots offered to facilities; accelerator networks (Start-Up Chile, Google for Startups).

Next milestones

  1. Controlled clinical study with wound-area endpoints
  2. Verified regulatory clearance
  3. First paying wound-care centre

Key risks

  • Weak evidence
  • Unverified compliance
  • Pre-seed funding only (US$30K total)

Opportunities

4 found in the network

Concrete moves for MedEtechni inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Distribution 1
  • Co-development 2
  • Investors 1

Distribution1

A channel or customer base to reach together

Route diabetic-wound patients from primary care

TIBOK runs AI-augmented primary care with chronic care monitored by Eva, and dermatology by photo, in Mauritius and soon Madagascar; diabetic patients with ulcers surface there first. A referral and pilot pathway could give MedEtechni a controlled multi-site setting in the Indian Ocean.

15%confidence

Evidence from the records

  • “chronic care led by the doctor and monitored by Eva”
  • “Real medical need”
If it works
A structured pilot cohort and an outcome-tracking channel.
First step
Discuss a pilot protocol with TIBOK's medical lead once regulatory status is verified.

Co-development2

An integration or joint product

Objective wound measurement from photos

MedEtechni's main weakness is evidence; Legit.Health's CE-marked AI assesses severity and monitors skin conditions from photos. Adapting it to measure wound evolution would give MedEtechni objective endpoints, and Legit.Health a new wound-care indication.

30%confidence

Evidence from the records

  • “Uncontrolled case study on 5 patients (chronic wounds)”
  • “Legit.Health is an AI-based medical device that helps dermatologists and doctors diagnose, assess the severity of and monitor skin diseases from photos.”
If it works
Credible, photo-based efficacy data for the next study.
First step
Ask Legit.Health whether its API can score wound images and propose a joint study protocol.

Real-world evidence via a Latin American hospital network

Cromodata runs a de-identified clinical data marketplace across dozens of hospitals in Latin America; MedEtechni needs wound-care baselines and sites for studies and data to train its AI triage tools.

25%confidence

Evidence from the records

  • “Argentine healthtech that runs a marketplace for de-identified clinical data for research and AI training, in partnership with dozens of hospitals (claimed network of 47 hospitals and 19M medical images).”
  • “AI tools for diagnosis, triage and hospital management”
If it works
Faster site recruitment and training data; a device-maker customer for Cromodata.
First step
Request Cromodata's catalogue of wound-care / diabetic foot datasets.

Investors1

A fund whose thesis fits

Global health-innovation accelerator

StartUp Health backs pre-seed/seed HealthTech founders globally and supported network member Wink Biotherapeutics; a physician-founder with a device-plus-AI story fits its 'health transformer' model.

20%confidence

Evidence from the records

  • “Physician founder”
  • “Real medical need”
If it works
Network access to US health systems for pilots.
First step
Ask Wink Biotherapeutics about their StartUp Health experience and apply.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Buenos Aires biotech fund and company builder backing pre-seed and seed Latin American life-science startups.

Puerto Rico UV phototherapy for chronic wounds — life-science-adjacent and Start-Up Chile-backed; device rather than biotech.

25%confidence

Evidence from the records

  • “"Pre-seed","Seed"”
  • “UV phototherapy for chronic wounds + AI clinical software”
  • “Uncontrolled case study on 5 patients (chronic wounds) and multicenter before/after study on surfaces published on the website”
Intro path
Founder-to-founder intro via Nanogrow Biotech (network portfolio company of GridX).
First step
Low priority; test interest in medtech.

Chilean VC that led BTrust's $1.5M seed; a Latin American fintech-leaning early-stage lead.

Puerto Rico chronic-wound medtech backed by Start-Up Chile — Chilean link but non-fintech.

20%confidence

Evidence from the records

  • “Chilean VC”
  • “UV phototherapy for chronic wounds + AI clinical software”
  • “Uncontrolled case study on 5 patients (chronic wounds) and multicenter before/after study on surfaces published on the website”
Intro path
Founder-to-founder intro via Btrust (network portfolio company of Invexor Venture Partners).
First step
Low priority.

Argentine VC that invested in Nanogrow Biotech's US$1.2M seed; thesis and ticket otherwise undocumented.

Puerto Rico UV phototherapy with AI clinical software at pilot: LatAm-adjacent medtech, very early.

15%confidence

Evidence from the records

  • “UV phototherapy for chronic wounds + AI clinical software”
  • “Pre-seed”
First step
Validate ATGen's medtech appetite first.

Investment analysis

3.5D

Grade D

Rank 111 of 151

Disruption5.0/10
Business model2.0/10
Market4.0/10
Risk(lower is better)8.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early.

Disruption

5/10

UVC phototherapy for chronic wounds: known approach.

Business model

2/10

Case study on 5 patients, claimed compliance without evidence.

Market

4/10

TAM chronic wound care ~$13.16bn (base 5), low scalability 4/10 (−1), no proven international expansion (0) → 4/10.

Risk

8/10

Lower is better

High risk: weak clinical evidence, regulation.

Strengths

  • Real medical need
  • Physician founder

Risks

  • Weak evidence
  • Unverified compliance

Funding

$30K, disclosed
  1. non daté

    pre-seed / accelerator (grant)included in US$30K total (CB Insights)

    Start-Up Chile (CORFO), BioLeap, OpenSeniors

  2. non daté

    support (nature not specified)not disclosed

    CORFO, Google for Startups (Cloud), ChileGlobal Ventures — listed as 'Backed by' on the website

  3. 2024-10

    prize / programnot disclosed

    Scale BCI Investment Readiness (claimed winner)

Amount used in the study. $30K (Start-Up Chile, not verified) according to CB Insights, lower bound 0.

Note. US$30K (CB Insights; not verified by a primary source)

Traction clarified based on the website (published studies, claimed certifications not documented). Note: MedEtechni represented Panama at the SWC (2025 edition, ISD tour); 2026 qualification not confirmed.

Team

  • Kevin Morales (Kevin Virgilio Morales Chamorro)

    Founder & CEO

    Physician specializing in biomedical innovation and health entrepreneurship, trained at the Georgia Institute of Technology (Chile).

  • Anabell Chamorro

    Cofounder & CFO

    Specialist in corporate finance and medtech investment strategy, Universitat de Barcelona.

  • Denis Pavon

    Cofounder & COO

    Expert in medical device operations and supply chain, Brunel University London.

Sources

Identification confidence
high
Founding year: 2018
2018 (PitchBook)
  1. 1medetechni.com/
  2. 2crunchbase.com/organization/medetechni
  3. 3pitchbook.com/profiles/company/608547-16
  4. 4cbinsights.com/company/medetechni/alternatives-competitors
  5. 5tvn-2.com/nacionales/jovenes-centroamerica-panama-compiten-startup-wo

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet